Announcement • Apr 25
Aelis Farma SA, Annual General Meeting, Jun 03, 2026 Aelis Farma SA, Annual General Meeting, Jun 03, 2026. Location: iecb 2 rue robert escarpit, pessac France New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 25% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (€2.3m revenue, or US$2.7m). Market cap is less than US$100m (€18.2m market cap, or US$21.3m). Announcement • Apr 07
Aelis Farma Receives €458,000 Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases Aelis Farma had been selected under the regional component of France 2030 in Nouvelle-Aquitaine and had been awarded a grant of EUR 458,000. This non-dilutive funding will help accelerate the Company’s research and development activities in the field of obesity and associated metabolic diseases. This non-dilutive public support, granted under the “Projet d’Avenir Innovation” call for projects, recognizes the scientific quality of the project led by Aelis Farma, its innovative nature, and its value creation potential in a rapidly expanding therapeutic field. The program was selected as part of the regional call for projects operated on behalf of the French State and the Nouvelle-Aquitaine Region, with the support of Bpifrance. The funds awarded will be used to finance research and development work focused on the identification and characterization of new drug candidates derived from the Company’s proprietary platform of specific signaling inhibitors of the CB1 receptor (CB1-SSi). This work is intended to advance the preclinical development of new molecules for the treatment of obesity-related metabolic disorders, as well as other peripheral diseases associated with dysregulation of the CB1 receptor. For Aelis Farma, this support strengthens both the external credibility of its “metabolism” program and its ability to secure competitive funding to support its development. It is fully aligned with the Company’s strategy to bring forward a new generation of treatments based on its proprietary CB1-SSi platform, with applications in both brain disorders and certain peripheral diseases. The regional component of France 2030 in Nouvelle-Aquitaine, presented by the Regional Prefecture, represents EUR 23 million over the 2025–2026 period, under a mechanism whereby each euro invested by the French State is matched by one euro invested by the Region. Aelis Farma is among the 8 new winners announced in this selection wave. Aelis Farma expresses its deep gratitude and wishes to acknowledge the key role played by the Nouvelle-Aquitaine Region, the Regional Prefecture and Bpifrance in supporting innovative high-potential projects capable of fostering the emergence of future French technology and biopharmaceutical leaders. This support reinforces the Company’s trajectory toward its value creation objectives and the development of breakthrough therapeutic innovations. 
